ARBUTUS BIOPHARMA CORPORATION

(ABUS)
  Rapporto
Tempo reale stimato Cboe BZX  -  16:26 30/06/2022
2.665 USD   -1.30%
28/06ARBUTUS BIOPHARMA CORPORATION: JMP Securities mantiene la raccomandazione Buy
MM
25/06Arbutus Biopharma Corporation presenta nuovi dati su AB-729, Ab-836 e AB-101 al Congresso Internazionale sul Fegato dell'EASL™ 2022 e fornisce un aggiornamento clinico su Ab-836.
CI
06/06Arbutus Biopharma, Vaccitech somministra il primo paziente nello studio che combina le terapie per il trattamento dell'epatite B cronica.
MT
RiassuntoQuotazioniGraficiNotizieRatingCalendarioSocietąFinanzaConsensusRevisioniDerivati 
RiassuntoTutte le notizieRaccomandazione analistiAltre lingueComunicati stampaPubblicazioni ufficialiNotizie del settore
Notizie in altre lingue su ARBUTUS BIOPHARMA CORPORATION
27/06Arbutus Presents New Data on AB-729, AB-836 and AB-101 at the EASL International Liver ..
27/06ARBUTUS BIOPHARMA: Presents New Data on AB-729, AB-836 and AB-101 at the EASL Internation..
27/06ARBUTUS BIOPHARMA CORP: Other Events, Financial Statements and Exhibits (form 8-K)
27/06TRANSCRIPT: Arbutus Biopharma Corporation - Special Call
25/06Arbutus Presents New Data on AB-729, AB-836 and AB-101 at the EASL International Liver ..
25/06Arbutus Presents New Data on AB-729, AB-836 and AB-101 at the EASL International Liver ..
25/06Arbutus Biopharma Corporation Presents New Data on AB-729, Ab-836 and AB-101 At the EAS..
09/06Arbutus to Present Seven Scientific Posters at EASL International Liver Congress 2022
08/06CONFERENCE CALL & WEBCAST TO DISCUSS: 00 am ET - Form 8-K
08/06ARBUTUS BIOPHARMA CORP: Other Events, Financial Statements and Exhibits (form 8-K)
08/06Arbutus to Present Seven Scientific Posters at EASL International Liver Congress™..
06/06Arbutus Biopharma, Vaccitech Dose First Patient in Trial Combining Therapies to Treat C..
06/06ARBUTUS BIOPHARMA: Corporate Presentation - June 2022
06/06ARBUTUS BIOPHARMA: and Vaccitech Dose First Patient in Phase 2a Clinical Trial Combining ..
06/06ARBUTUS BIOPHARMA CORP: Other Events, Financial Statements and Exhibits (form 8-K)
06/06Arbutus and Vaccitech Dose First Patient in Phase 2a Clinical Trial Combining Therapies..
06/06Arbutus and Vaccitech Dose First Patient in Phase 2a Clinical Trial Combining Therapies..
06/06Arbutus Biopharma Corporation and Vaccitech plc Dose First Patient in Phase 2a Clinical..
03/06ARBUTUS BIOPHARMA: Update on AB-729 and AB-836, an siRNA and capsid inhibitor currently i..
02/06Arbutus to Participate in June Investor Conferences
02/06Arbutus to Participate in June Investor Conferences
31/05ARBUTUS BIOPHARMA CORP: Change in Directors or Principal Officers, Submission of Matters ..
26/05ARBUTUS BIOPHARMA: Announces Abstract Selected for Publication at the 2022 American Socie..
26/05ARBUTUS BIOPHARMA CORP: Other Events, Financial Statements and Exhibits (form 8-K)
26/05Arbutus Announces Abstract Selected for Publication at the 2022 American Society of Cli..
26/05Arbutus Announces Abstract Selected for Publication at the 2022 American Society of Cli..
24/05ARBUTUS BIOPHARMA CORP: Other Events, Financial Statements and Exhibits (form 8-K)
17/05Arbutus to Present at H.C. Wainwright Global Investment Conference
05/05ARBUTUS BIOPHARMA CORP MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND..
05/05TRANSCRIPT: Arbutus Biopharma Corporation, Q1 2022 Earnings Call, May 05, 2022
05/05ARBUTUS: Q1 Earnings Snapshot
05/05Earnings Flash (ABUS) ARBUTUS BIOPHARMA CORPORATION Reports Q1 Revenue $12.6M, vs. Stre..
05/05ARBUTUS BIOPHARMA CORP: Results of Operations and Financial Condition, Other Events, Fina..
05/05Arbutus Biopharma Corporation Reports Earnings Results for the First Quarter Ended Marc..
05/05Arbutus Reports First Quarter 2022 Financial Results and Provides Corporate Update
05/05Arbutus Reports First Quarter 2022 Financial Results and Provides Corporate Update
21/04Arbutus to Report First Quarter 2022 Financial Results and Provide Corporate Update
18/03Canadian Pfizer partner sues to head off patent lawsuit over COVID-19 vaccine
17/03Alnylam files patent infringement lawsuits against Pfizer, Moderna
11/03Moderna Has Standing To Appeal Because Of Risk Of Infringement Suit, But PTAB's Rejecti..
03/03ARBUTUS BIOPHARMA CORP: Other Events, Financial Statements and Exhibits (form 8-K)
03/03ARBUTUS BIOPHARMA CORP Management's Discussion and Analysis of Financial Condition and..
03/03ARBUTUS: Q4 Earnings Snapshot
03/03TRANSCRIPT: Arbutus Biopharma Corporation, Q4 2021 Earnings Call, Mar 03, 2022
03/03ARBUTUS BIOPHARMA: Reports Fourth Quarter and Year End 2021 Financial Results and Provide..
03/03ARBUTUS BIOPHARMA: Corporate Presentation - March 2022
03/03ARBUTUS BIOPHARMA CORP: Results of Operations and Financial Condition, Other Events, Fina..
03/03Arbutus Biopharma Corporation Reports Earnings Results for the Full Year Ended December..
03/03Arbutus Reports Fourth Quarter and Year End 2021 Financial Results and Provides Corpora..
03/03Arbutus Provides Pipeline Updates
03/03NORTH AMERICAN MORNING BRIEFING: Oil Prices Top -3-
03/03Timing Is Everything – Intervening Loss In Standing Results In Dismissal Of First..
01/03What you need to know about the coronavirus right now
01/03Moderna Faces US Lawsuit From Arbutus For Allegedly Infringing Patents Used For COVID-1..
28/02Health Care Down as Risk Aversion Weighs on Biotech -- Health Care Roundup
28/02Arbutus files patent infringement lawsuit against Moderna related to COVID shot
28/02Arbutus Biopharma, Genevant Sciences File Patent Infringement Lawsuit Against Moderna
28/02ARBUTUS BIOPHARMA CORP: Other Events (form 8-K)
28/02Arbutus files patent infringement lawsuit against Moderna
28/02Arbutus Biopharma and Genevant Sciences File Patent Infringement Lawsuit Against Modern..
28/02Arbutus Biopharma and Genevant Sciences File Patent Infringement Lawsuit Against Modern..
28/02ARBUTUS BIOPHARMA: Inhibition of PAPD5 and PAPD7 by Small-Molecule HBV RNA Destabilizers ..
17/02Arbutus to Report Fourth Quarter and Year End 2021 Financial Results and Provide Corpor..
17/02Arbutus to Report Fourth Quarter and Year End 2021 Financial Results and Provide Corpor..
24/01ARBUTUS BIOPHARMA: Corporate Presentation - January 2022
24/01ARBUTUS BIOPHARMA: Announces 2022 Corporate Objectives and Provides Financial Update - Fo..
24/01ARBUTUS BIOPHARMA CORP: Results of Operations and Financial Condition, Other Events, Fina..
24/01Arbutus Announces 2022 Corporate Objectives and Provides Financial Update
24/01Arbutus Announces 2022 Corporate Objectives and Provides Financial Update
04/01Arbutus to Participate at H.C. Wainwright Bioconnect Virtual Conference
2021Roivant Sciences Up 28%, Continuing Increase
2021MODERNATX, INC. V. ARBUTUS BIOPHARMA: Sublicense Not Enough To Show Standing
2021Patent Case Summaries | Week Ending December 3, 2021
2021Arbutus, Antios Dose First Patient in Phase 2a Trial with AB-729, ATI-2173 for Hepatiti..
2021ARBUTUS BIOPHARMA: Antios Therapeutics and Arbutus Biopharma Announce First Patient Dosed..
1  2  3  4  5  6  7  8Succ.
Prossimo evento su ARBUTUS BIOPHARMA CORPORATION